Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit

ATLANTA -

- Growing Outcomes Evidence Spurs Renewed Interest in Unique Heart Valve Procedure

CryoLife’s Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World

ATLANTA -

- The Ross Summit 2009 to focus on new patient data supporting the Ross heart reconstruction procedure and the use of SynerGraft(R) processed human heart valves in the Ross Procedure

CryoLife Receives CE Mark Approval for BioFoam(R) Hemostatic Technology

ATLANTA -

CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced it has received CE mark approval for its BioFoam(R) Surgical Matrix (BioFoam). The CE mark allows immediate, unrestricted commercial distribution of BioFoam in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. BioFoam is the second product from the Company’s protein hydrogel technology platform to receive a CE mark.